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Abstract
Background: P16 and p53 protein expression, and high-risk human papillomavirus (HPV-HR) types have been
associated with survival in head and neck cancer (HNC). Evidence suggests that multiple molecular pathways need
to be targeted to improve the poor prognosis of HNC. This study examined the individual and joint effects of
tumor markers for differences in predicting HNC survival. P16 and p53 expression were detected from formalin-
fixed, paraffin-embedded tissues by immunohistochemical staining. HPV DNA was detected by PCR and DNA
sequencing in 237 histologically confirmed HNC patients.
Results: Overexpression of p16 (p16+) and p53 (p53+) occurred in 38% and 48% of HNC tumors, respectively. HPV-
HR was detected in 28% of tumors. Worse prognosis was found in tumors that were p53+ (disease-specific
mortality: adjusted hazard ratios, HR = 1.9, 95% CI: 1.04-3.4) or HPV- (overall survival: adj. HR = 2.1, 1.1-4.3) but no
association in survival was found by p16 status. Compared to the molecular marker group with the best prognosis
(p16+/p53-/HPV-HR: referent), the p16-/p53+/HPV- group had the lowest overall survival (84% vs. 60%, p < 0.01; HR
= 4.1, 1.7-9.9) and disease-specific survival (86% vs. 66%, p < 0.01; HR = 4.0, 1.5-10.7). Compared to the referent, the
HRs of the other six joint biomarker groups ranged from 1.6-3.4 for overall mortality and 0.9-3.9 for disease-specific
mortality.
Conclusion: The p16/p53/HPV joint groups showed greater distinction in clinical outcomes compared to results
based on the individual biomarkers alone. This finding suggests that assessing multiple molecular markers in HNC
patients will better predict the diverse outcomes and potentially the type of treatment targeted to those markers.
Background
Infection with human papillomavirus high risk (HPV-
HR) types is causally related to the development of
HNC independent of tobacco and alcohol use [1-3].
HPV infection has been demonstrated to play a role in
the molecular pathways through its viral oncoproteins,
E6 and E7. These proteins increase degradation of p53
and interfere with pRb function leading to upregulation
of p16
INK4a by loss of negative feedback control [4].
P16
INK4a and TP53 are tumor suppressor genes and key
targets in the loss of cell cycle control [5]. Overexpres-
sion of p16 (p16+) in HPV-HR infection has been
demonstrated in a high percentage of cervical and HNC
cancers [5-7] and it has been suggested that p16
INK4a
expression may serve as a surrogate biomarker of onco-
genic HPV infection in predicting HPV-related tumors
[8,9]. Better prognosis has been shown in HPV-HR [10]
and in p16+ HNC tumors [7,9,11]. However, the signals
and pathways that determine p16 expression in humans
[12] or upregulation in HPV-related tumors are not well
understood. Although p53 serves an important role in
carcinogenesis, it is a controversial prognostic indicator
with some studies showing p53 expression linked to
decreased HNC survival [7,8,13] and others finding no
correlation [12,14,15]. TP53 wild type has been shown
to be highly correlated with HPV infection in HNC
whereas TP53 mutations are rare in infected tumors
[16,17]. A large investigation [16] found that HPV HNC
tumors had higher overall survival after adjusting for the
effect of TP53 mutation. We have shown that disease-
specific and recurrence-free survival were highest in the
joint biomarkers p16+/HPV-HR and p53-/HPV-HR
HNC tumors, and lowest in p16-/HPV- and p53+/HPV-
tumors, and survival was intermediate but different
among the other joint p16/HPV and p53/HPV
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of HNC based on multiple biomarkers need to be evalu-
ated jointly to more accurately determine clinical
outcomes and possibly alternative, targeted treatment
regimens [7,13].
Although some studies have examined the association
between two joint markers, p16, p53, or HPV, in HNC
[7,8,12,16,18], few have evaluated their joint effects on
survival. None has evaluated the additional clinical
outcome that evaluating three biomarker tests might
provide, a common practice in medicine to perform
multiple different diagnostic assessments. Previous
investigations have adjusted one marker to examine the
risks and outcomes associated with another marker of
interest; however, because of the potential differences in
the molecular pathways leading to tumorigenesis, the
joint effects of these genes need to be evaluated. By
joint effect we are referring to an examination of the
combined markers, p16, p53, and HPV, as eight distinct
tumor groups with the potential for as many different
clinical outcomes; and with different effects associated
with other risk factors and confounders (e.g., tobacco,
stage). Among those that have attempted to examine
joint effects, none has examined multiple markers
adjusting for effects of age, stage, tobacco or alcohol use
[18,19]. Thus, the prognostic significance associated
with alterations in multiple molecular markers remains
unclear. This investigation presents a large group of
newly diagnosed HNC cases examined for the associa-
tion by joint p16, p53, and HPV-HR status in HNC
tumors to evaluate their effects on survival.
Results
Risk Factors and Pathologic Characteristics by p16, p53
and HPV Status
Among the 237 HNC cases, 61% were male and the
average patient age was 60 years. P16 (p16+) was over-
expressed in 38%, p53 (p53+) was overexpressed in 48%,
and HPV-HR was detected in 28% of HNC tumors.
When examined by site, 68% of the oropharyngeal, 28%
of the oral cavity, and 16% of the laryngeal cancers were
p16+; p53+ prevalence was 47% in the oropharynx, 46%
in the oral cavity, and 59% in the larynx; and 63% of the
oropharynx, 15% of the oral cavity, and 9% of the larynx
tumors were HPV-HR positive. There were three HPV-
HR types detected: 94% were HPV-16, 5% HPV-33, and
1% HPV-18.
Table 1 shows the association and p-values between
p16, p53, and HPV outcome status and potential risk fac-
tors and pathologic characteristics of HNC, first for all
HNC histologic types and separately for SCC. Reverence
to protein overexpression or positive infection status is
noted by the “+” symbol and lack of expression or HPV
negative for infection by the “-” symbol. After adjusting
for age, alcohol, tobacco and the other biomarkers, p16+
was associated with a significantly reduced risk of p53
expression (OR = 0.5, 95% CI: 0.2-0.9) and a higher risk
of in HPV-HR detection in tumors (OR = 16.1, 7.6-33.9).
P53+ showed an inverse relationship with p16+ but was
not significantly related to patient characteristics or HPV
status. In addition to the significant association with p16
+ status, HPV-HR was associated with alcohol (≥ 1-21
drinks/week: OR = 2.4, 0.9-6.0, >21 drinks/week: OR =
2.7, 0.9-7.9) and tobacco use (>0-30 pack-years: OR =
6.4, 2.1-19.3). P16 overexpression and HPV-HR were
significantly higher in oropharyngeal (OR = 4.0, 1.1-13.8,
OR = 8.4, 1.8-38.2 respectively) but not in oral cavity
compared to laryngeal tumors. Later stage (IV, OR = 2.6,
1.2-5.7) and higher grade (OR = 2.0, 0.97-4.3) were more
likely to be detected in p16+, and positive nodal involve-
ment was more frequently found in p16+ (OR = 2.1,
1.05-4.0) and HPV-HR (OR = 2.1, 0.99-4.4) cancers.
Tumor site and pathologic characteristics were not
r e l a t e dt op 5 3s t a t u s .T a b l e1s h o w st h a tn o n S C Cc a s e s
were more likely than SCC cases to be p16+ (55% vs.
36%) but less likely to be HPV-HR (14% vs. 29%,). Find-
ings limited to SCC showed greater risk of HPV-HR
among males (p = 0.05), moderate and heavy alcohol-
related users (≥ 1-21: p = 0.002; >21: p = 0.02),
oropharynx (p = 0.008); and greater risk of p16+ in poor/
undifferentiated tumors (p = 0.02).
The eight p16/p53/HPV joint biomarker groups also
were compared for potential differences in risk factors,
adjusting for age, tobacco, and alcohol use with each
group compared to the p16+/p53-/HPV-HR group (data
not shown). This group was chosen as the referent on
the basis of our previous research [7,10,13] and the find-
ings in this study regarding the biomarker group with
the best survival outcome. All analyses examined both
SCC separately and all histologic groups, with no differ-
ences in findings. The two biomarker groups that were
both p16- and HPV- were significantly less likely to
include males: p16-/p53+/HPV- and p16-/p53-/HPV-
(p = 0.04-0.01). Moderate use of tobacco (>0 ≤ 30 pack-
years) was more frequent in the referent (41%) than in
the three groups that were HPV- (p16+/p53-/HPV-
10%, p16-/p53-/HPV- 25%, and p16+/p53+/HPV- 13%;
p = 0.07-0.02); heavy tobacco use (>30 pack-years) also
was less frequently reported in the p16+p53+HPV-
group (38% versus 49%, p = 0.03). Assessment of tumor
characteristics indicated that all joint groups, except p16
+/p53+/HPV-HR, were less likely to have later stage (p
= 0.03 < 0.002) and nodal involvement (p = 0.01-<0001)
compared to the referent. These findings are similar to
the individual biomarkers shown in table 1. Except for
p16+/p53+/HPV-HR, all joint groups were less likely
to be detected in the oropharynx (p = 0.02 < 0.0001)
compared to the referent.
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Page 2 of 10Table 1 Risk Factors and Pathologic Characteristics of HNC by p16, p53, and HPV Status for All Histologic and SCC
1
Histologic Types
Characteristics p16- p16+ All/SCC p53+ p53- All/SCC HPV- HPV-HR All/SCC
N = 148
(%)
N=8 9
(%)
p-value
2 N = 114
(%)
N = 123
(%)
p-value
2 N = 171
(%)
N=6 6
(%)
p-value
2
Gender
Female 64 (43.2) 28 (31.5) 49 (43.0) 43 (35.0) 75 (43.9) 17 (25.8)
Male 84 (56.8) 61 (68.5) 0.5/0.7 65 (57.0) 80 (65.0) 0.5 96 (56.1) 49 (74.2) 0.1/0.05
Age Group
≤ 55 years 48 (32.4) 41 (46.1) 0.2/0.2 37 (32.5) 52 (42.3) 0.4 58 (33.9) 31 (47.0) 0.6/0.4
>55 years 100 (67.6) 48 (53.9) 77 (67.5) 71 (57.7) 113 (66.1) 35 (53.0)
Alcohol
Never 45 (30.6) 22 (24.7) 31 (27.5) 36 (29.2) 55 (32.4) 12 (18.2)
≥ 1-21 58 (39.5) 39 (43.8) 0.9/0.2 45 (39.8) 52 (42.3) 0.6 66 (38.8) 31 (47.0) 0.06/0.002
>21 44 (29.9) 28 (31.5) 0.8/0.4 37 (32.7) 35 (28.5) 0.3 49 (28.8) 23 (34.8) 0.08/0.02
Tobacco
Never 34 (23.1) 19 (21.4) 26 (22.8) 27 (22.5) 45 (26.4) 8 (12.1)
>0-30 38 (25.9) 27 (30.3) 0.2/0.4 32 (28.1) 33 (27.0) 0.7 37 (21.8) 28 (42.4) 0.001/0.007
>30 75 (51.0) 43 (48.3) 0.9/0.3 56 (49.1) 62 (50.8) 0.97 88 (51.8) 30 (45.5) 0.3/0.8
p16 Status
Positive - - - 32 (28.1) 57 (46.3) 36 (21.1) 53 (80.3) < 0.0001/
< 0.0001
Negative - - - 82 (71.9) 66 (53.7) 0.03 135 (78.9) 13 (19.7)
p53 Status
Positive 82 (55.4) 32 (36.0) 0.03/0.02 - - - 88 (51.5) 26 (39.4) 0.99/0.9
Negative 66 (44.6) 57 (64.0) - - - 83 (48.5) 40 (60.6)
HPV Status
HR 13 (08.8) 53 (59.6) 26 (22.8) 40 (32.5) 0.98 - - -
Negative
3 135 (91.2) 36 (40.4) < .0001/< 0.001 88 (77.2) 83 (67.5) - - -
Site
Oropharynx 22 (14.9) 46 (51.7) 0.03/0.05 32 (28.1) 36 (29.3) 0.8 25 (14.6) 43 (65.2) 0.01/0.008
Oral Cavity 99 (66.9) 38 (42.7) 0.3/0.4 63 (55.) 74 (60.1) 0.4 117 (68.4) 20 (30.3) 0.99/0.97
Larynx/Hypo
4 27 (18.2) 5 (5.6) 19 (16.7) 13 (10.6) 29 (17.0) 3 (4.5
Stage
0/I/II 56 (38.1) 14 (15.7) 35 (30.7) 35 (28.7) 60 (35.3) 10 (15.2)
III 25 (17.0) 17 (19.1) 0.2/0.2 20 (17.5) 22 (18.0) 0.6 28 (16.5) 14 (21.2) 0.2/0.4
IV 66 (44.9) 58 (65.2) 0.02/0.01 59 (51.8) 65 (53.3) 0.5 82 (48.2) 42 (63.6) 0.2/0.6
Tumor Grade
Well/Mod 118 (81.4) 55 (64.0) 87 (77.7) 86 (72.3) 132 (78.6) 41 (65.1)
Poor/Undif
5 27 (18.6) 31 (36.0) 0.06/0.02 25 (22.3) 33 (27.7) 0.7 36 (21.4) 22 (34.9) 0.6/0.7
Nodal Involvement
Yes 59 (40.1) 61 (68.5) 0.04/0.04 53 (46.9) 67 (54.5) 0.9 73 (42.9) 47 (71.2) 0.05/0.2
No 88 (59.9) 28 (31.5) 60 (53.1) 56 (45.5) 97 (57.1) 19 (28.8)
Histology
SCC 138 (93.2) 77 (86.5) 0.08 106 (93.0) 109 (88.6) 0.2 152 (88.9) 63 95.4) 0.1
nonSCC 10 (6.8) 12 (13.5) 8 (7.0) 14 (11.4) 19 (11.1) 3 (4.6)
1 SCC = squamous cell carcinoma;
2The left side of slash p-value is in reference to All histologies and the right side p-value refers to SCC only; the p-value is in
reference to positive vs. negative biomarker status for each risk factor, p-values are adjusted for age, alcohol, tobacco, p16, p53, and HPV;
3 HPV negative (-) for
all low-risk and high-risk HPV types;
4 Hypo = Hypopharynx;
5 Undif = Undifferentiated.
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There were 237 cases with overall survival data, 234
cases with disease-specific survival (3 cases could not be
classified as free of disease), and 203 cases with data on
recurrence-free survival (31 cases were never disease-
free). The median time to death or last follow-up for
the HNC cases was 1.9 years (range 0.03-10.1 years) for
overall survival and 1.8 years for disease-specific survival
(range: 0.03-10.1 years). There were 73 deaths in the
overall survival, 51 in disease-specific survival, and 46
with recurrence.
Table 2 shows the median survival for cases based on
the individual and joint biomarker groups and for all
histologies combined and SCC separately. Those who
had tumors that were either p16+ or HPV-HR had signif-
icantly higher median years of overall, disease-specific,
and recurrence-free survival, whereas p53 status was
unrelated to survival time. When we compared SCC to
nonSCC (data not shown), nonSCC cases had longer
median years of disease-specific survival in the p53+ (2.8
years vs. 1.7 years) and HPV-HR groups (2.9 vs. 2.3); and
had longer median years of recurrence-free survival for
individual biomarker comparisons (p16-: 2.3 vs. 1.4; p53-:
2.7 vs. 1.9; HPV-HR: 3.1 vs. 2.3; HPV-: 2.2 vs. 1.4).
More survival distinctions were apparent in the joint
marker analyses. Median survival associated with the three
survival outcomes were near or significantly longer in the
referent group (p16+/p53-/HPV-HR) compared to four
other marker groups, all of which were p16- and/or HPV-
(p16-/p53+/HPV-HR, p16-/p53+/HPV-, p16+/p53-/HPV-,
and p16-/p53-/HPV-). The other three joint biomarker
groups (p16-/p53-/HPV-HR, p16+/p53+/HPV-HR, and
p16+/p53+/HPV-) had similar 2-year overall, disease-speci-
fic, and recurrence-free survival to that of the referent.
These three groups were p16+ and/or HPV-HR, thus
having the opposite marker status to that of the worse med-
ian survival groups. When analyses were limited to SCC,
results were similar (table 2), although the p16+/p53+/
HPV- group reported nonstatistically significantly worse
median survival than the combined histologic group
(table 2).
Table 3 presents the adjusted hazard ratios for overall
survival and disease-specific survival of HNC associated
with the three biomarkers, individually and jointly, for all
histologic types and SCC. Because of the reduced sample
size to assess recurrence-free analyses by the joint groups,
power was low and data were not presented in the table.
Multivariate analysis demonstrated that p16, p53, HPV,
age, and stage were independently associated with survival
and thus were included in the adjustments whereas alco-
hol, tobacco, tumor site, and treatment were not indepen-
dently significantly associated with survival and were
excluded. For all histologies, tumors that were p16- had
only slightly worse disease-specific survival compared to
p16+ tumors; those that were p53+ had significantly worse
disease-specific survival for all histologies and SCC
patients only; and HPV- cases had significantly worse
overall survival and elevated disease-specific mortality for
combined and SCC histologies. Recurrence-free survival
for all histologies (data not shown) was worse among
those who were p16- (HR = 2.9, 1.2-6.9), or p53+ (HR =
2.3, 1.2-4.4) whereas HPV was not related to recurrence
Table 2 Frequency and Median Years of Overall, Disease-Specific and Recurrence-free Survival by p16/p53/HPV Status
Overall Survival Disease-specific Survival Recurrence-free Survival
(N = 203)
All Histologies
N = 237
SCC
N = 215
All Histologies
N = 234
SCC
N = 212
All Histologies
N = 203
SCC
N = 185
p16/p53/HPV
Status
N
1 SCC
(N)
1
Median p-
value
2
Median p-
value
2
Median p-
value
2
Median p-
value
2
Median p-
value
2
Median p-
value
2
p16+ 89 77 2.3 referent 2.3 referent 2.3 referent 2.3 referent 2.3 referent 2.3 referent
p16- 148 138 1.7 0.009 1.7 0.01 1.7 0.008 1.7 0.01 1.4 0.0001 1.4 < 0.001
p53- 123 109 2.0 referent 2.0 referent 1.9 referent 1.9 referent 1.9 referent 1.9 referent
p53+ 114 106 1.7 0.39 1.7 0.24 1.7 0.41 1.7 0.25 1.6 0.17 1.5 0.15
HPV-HR 66 63 2.3 referent 2.3 referent 2.3 referent 2.3 referent 2.5 referent 2.3 referent
HPV-
2 171 152 1.7 0.002 1.6 0.001 1.6 0.002 1.6 0.001 1.5 0.0008 1.4 < 0.001
p16+/p53-/HPV-HR 37 36 2.3 referent 2.3 referent 2.3 referent 2.3 referent 2.7 referent 2.6 referent
p16-/p53-/HPV-HR 3 2 2.8 0.77 3.1 0.46 2.8 0.77 3.1 0.46 1.9 0.50 1.9 0.54
p16+/p53+/HPV-HR 16 15 2.8 0.93 2.8 0.93 2.8 0.93 2.8 0.93 2.7 0.48 2.5 0.48
p16-/p53+/HPV-HR 10 10 1.3 0.07 1.3 0.09 1.3 0.07 1.3 0.09 1.0 0.02 1.0 0.03
p16-/p53+/HPV- 72 69 1.6 0.004 1.6 0.006 1.6 0.003 1.6 0.006 1.4 0.0001 1.4 < 0.001
p16+/p53-/HPV- 20 14 1.2 0.01 1.1 0.07 1.2 0.01 1.1 0.07 1.2 0.008 0.9 0.05
p16-/p53-/HPV- 63 57 1.8 0.02 1.8 0.01 1.8 0.02 1.7 0.01 1.5 0.001 1.4 < 0.001
p16+/p53+/HPV- 16 12 2.4 0.47 1.3 0.22 2.4 0.47 1.3 0.22 2.7 0.68 1.9 0.35
1Number of cases with survival data;
2 p-value for differences in median years within biomarker status,
3 HPV- for all low-risk and high-risk HPV types.
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was elevated among those who were p16- (HR = 2.1, 0.8-
5.4), worse for p53+ (2.1, 1.1-4.6) and not related to HPV
(HR = 1.3, 0.5-3.2).
Next the biomarkers were evaluated as joint groups
for prognosis (table 3). In contrast to the referent (p16
+/p53-/HPV-HR), the p16-/p53+/HPV- group had the
lowest overall survival (adj. HR = 4.1, 84% vs. 60%, p <
0.01), disease-specific survival (HR = 4.0; 86% vs. 66%, p
< 0.01), and recurrence-free survival (HR = 19.7, 50%
versus 0%, p < 0.0001; data not shown). Overall survival
was worse among all groups that had HPV- status (table
3 and figure 1) whereas the same was true for disease-
specific survival in three of the p53+ groups: p16-/p53
+/HPV-HR, p16-/p53+/HPV-, p16+/p53+/HPV- (table 3
and figure 2). Two other joint groups, p16+/p53-/HPV-
and p16-/p53-/HPV-, had elevated but not statistically
significant worse disease-specific survival risks, likely
due to the more limited number of cases in those
groups. For combined histologies, all joint groups except
p16+/p53-/HPV- and p16+/p53+/HPV- had significantly
higher risk of recurrence compared to the referent
group (HRs = 8.6-19.7, p = 0.04- < 0.004; figure 3)
although CIs were wide (data not shown in table). The
HRs for p16+ p53-/HPV- and p16+/p53+/HPV- also
were elevated (5.9, 0.5-66.9, p = 0.15; 5.5, 0.5-64.0, p =
0.17, respectively). Table 3 also shows that when SCC
cases were examined, only the p16+/p53+/HPV- group
showed worse HRs, compared to the joint histologies,
for overall (4.6 vs. 3.3), disease-specific (4.6 vs. 2.9), and
recurrence-free survival HR (9.1 vs. 5.5, 17% vs. 12%,
data not shown), respectively. For SCC cases, p16-/p53
+/HPV-, had the highest risk of recurrence (HR = 19.7,
CI: 2.5-152.2, p-value = .004)) followed by p16-/p53
+/HPV-HR (HR = 16.6, CI: 2.1-130.1, p-value = 0.004).
Other risk factors for survival included age which
showed a small increased risk per year with prognostic
outcomes (table 3). Patients with stages III/IV disease
had significantly worse overall survival and even worse
disease-specific survival but not recurrence (HR = 1.3,
0.7-2.5) compared to earlier stage tumors. Two-way
interactions between the biomarkers showed no
Table 3 Adjusted
1 Hazard Ratio for Overall and Disease-specific Survival
Risk Factors Overall Survival HR (95% CI) Disease-Specific Survival HR (95% CI)
All Histologies N = 237 SCC N = 215 All Histologies N = 234 SCC N = 212
p16 Status
p16- 1.2 (0.7-2.2)
1 0.9 (0.5-1.7) 1.5 (0.7-3.1)
1 1.0 (0.5-2.2)
p16+ referent referent referent referent
p53 Status
p53- referent referent referent referent
p53+ 1.4 (0.9-2.2)
1 1.3 (0.8-2.2) 1.9 (1.04-3.4)
1 1.9 (1.01-3.5)
HPV Status
HPV-HR referent referent referent referent
HPV- 2.1 (1.1-4.3)
1 2.6 (1.2-5.3) 1.6 (0.7-3.7)
1 2.1 (0.9-4.8)
p16/p53/HPV Status
3
p16+/p53-/HPV-HR referent referent referent referent
p16-/p53-/HPV-HR NE
3 NE
3 NE
3 NE
3
p16+/p53+/HPV-HR 1.6 (0.4-5.7) 1.8 (0.5-6.3) 0.9 (0.2-4.7) 1.0 (0.2-5.3)
p16-/p53+/HPV-HR 3.2 (0.8-13.4) 2.8 (0.7-11.5) 3.9 (0.9-16.9) 3.4 (0.8-14.9)
p16-/p53+/HPV- 4.1 (1.7-9.9) 3.7 (1.5-9.0) 4.0 (1.5-10.7) 3.7 (1.4-9.9)
p16+/p53-/HPV- 2.9 (0.9-9.1) 3.6 (1.1-11.1) 1.7 (0.4-7.3) 2.2 (0.5-9.2)
p16-/p53-/HPV- 3.1 (1.2-7.9) 3.2 (1.2-8.2) 1.9 (0.6-5.7) 1.9 (0.6-5.9)
p16+/p53+/HPV- 3.4 (1.1-10.3) 4.6 (1.4-14.5) 2.9 (0.8-10.3) 4.6 (1.3-16.1)
Age
2 1.03 (1.01-1.05) 1.04 (1.02-1.1) 1.03 (1.01-1.05) 1.04 (1.01-1.1)
Stage
I/II referent referent referent referent
III/IV 3.1 (1.7-5.9) 3.1 (1.6-6.0) 4.6 (1.9-10.9) 4.5 (1.9-11.0)
1Adjusted for p16, p53, HPV, age, and stage;
2NE = not estimable due small sample size
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HPV for any of the clinical outcomes (p > 0.10, data not
shown). The 3-way interaction among the biomarkers
could not be examined for survival because there were
too few deaths among the HPV-HR group whereas the
3-way interaction for recurrence showed a near signifi-
cant interaction effect (p > 0.05- < 0.1). None of the
tests for additive interactions was statistically significant.
We examined two-year survival rates (data not shown)
for comparison with the survival analyses (table 3). Only
the p16-/p53+/HPV- group had significantly worse
adjusted (age, stage) two-year overall (83% versus 54%,
adj. p = 0.003) and disease-specific survival (86% vs. 54%,
adj. p = 0.002) compared to the referent group. One
other joint molecular group (p16+/p53+/HPV-HR) had
similar overall and disease-specific survival to the
Figure 1 Overall survival by p16, p53, and HPV status. Survival curves based on the Kaplan-Meier method. Significance was based on Log-
rank comparisons of each group to the reference group, p16+/p53-/HPV-HR.
Figure 2 Disease-specific survival by p16, p53, and HPV status. Survival curves based on the Kaplan-Meier method. Significance was based
on Log-rank comparisons of each group to the reference group, p16+/p53-/HPV-HR.
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Page 6 of 10referent while the other joint groups had nonsignificantly
lower two-year survival (data not shown). There were no
recurrences (0%) at two years in the referent group,
p16+/p53-/HPV-HR, whereas recurrence for the same
period ranged between 17% and 51% in the other joint
marker groups: p16-/p53+/HPV- (51%, p = 0.0001), adj.
p16-/p53-/HPV- (30%, adj. p = 0.004), p16+/p53-/HPV-
group (25%, p = 0.06), p16+/p53+/HPV- (20%, p = 0.09),
and p16+/p53+/HPV-HR (17%, p = 0.12). The p16-/
p53-/HPV-HR and p16-/p53+/HPV-HR groups had
inadequate numbers of cases to evaluate two-year recur-
rence. There were no major differences in survival when
histology was limited to SCC.
Since effectiveness of initial treatment may be influ-
enced by the status of the molecular markers, patients
were examined for disease-specific survival by therapy
(data not shown). Compared to the oropharynx, cancers
o ft h eo r a lc a v i t yw e r em o r el i k e l yt or e c e i v es u r g e r y
(48% vs. 12%) or surgery/XRT (44% vs. 26%) and less
likely to be treated by XRT (2% vs. 28%) or XRT/che-
motherapy (1% vs. 25%). Because of small numbers, ana-
lyses could not be examined by site and could only be
calculated for a few joint biomarker groups. Compared
to the referent (p16+/p53-/HPV-HR), the worst survival
group, p16-/p53+/HPV-, had a higher frequency of dis-
ease-specific deaths whether treated by radiation (XRT:
0% vs. 50%, p = 0.02) or surgery/XRT (15% vs. 36%, p >
0.05) controlling for stage. The p16-/p53+/HPV-
patients also had worse recurrence-free survival com-
pared to the referent group for radiation (0.0% versus
56%, p = 0.04, unadjusted) and for surgery/XRT (10%
v s .3 6 % ,p>0 . 0 5 ,a d j u s t e df o rs t a g e )b u tn o tf o ro t h e r
treatments. All other biomarker groups showed no dif-
ference in recurrence by treatment modality for all
histologies combined or for treatment limited to SCC.
Discussion
Although it is well-established that head and neck
tumors detected with HPV oncoproteins, p16 overex-
pression, or p53 wild type, have better clinical outcomes,
our study provides further insight into the molecular
pathways of these tumor markers. The results show that
there are different prognostic outcomes when these
markers are examined together in tumors compared to
outcomes based on single marker findings that one
would not have predicted. This finding suggests that
assessing multiple molecular markers in HNC patients
at the time of diagnosis or treatment will better predict
clinical outcomes and potentially the type of treatment
targeted to those markers to improve prognosis.
Furthermore, despite evaluations of HNC limited to
SCC, clinical outcomes were heterogeneous, suggesting
that molecular characteristics are more important for prog-
nosis. In our large clinical population followed for almost a
decade, we have shown that HNC patients who have the
combined tumor markers which individually are associated
with better prognosis, p16+, p53-, and HPV-HR, also have
the best clinical outcomes whereas those with the opposite
status markers, p16-, p53+, and HPV-, have the worst
disease-specific and recurrence-free survival.
Figure 3 Recurrence-free survival by p16, p53, and HPV status. Survival curves based on the Kaplan-Meier method. Significance was based
on Log-rank comparisons of each group to the reference group, p16+/p53-/HPV-HR.
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Page 7 of 10In contrast, the other six joint biomarker groups had
clinical outcomes different from each other that were
not predictable based on the individual biomarker
results. Distinctions in survival in these joint groups,
compared to the single markers, remained after the
hazard ratios for the individual markers were adjusted
for the other two biomarkers. What this suggests is that
the difference in survival outcomes may be due to inter-
actions among the various molecular markers which
multivariate analyses cannot detect by simple adjust-
ment for confounding. Because of limitations in sample
size in some of the joint groups, this hypothesis is still
not altogether clear from our data and needs further
investigation. The most distinctive finding was that no
single marker in the joint effects groups was consistently
pivotal for predicting worse overall, disease-specific, and
recurrence-free survival hazard ratios. Although most
biomarker groups had higher disease-specific mortality
than the referent, among the worst disease-specific HRs
were two joint groups that included p16-/p53+ regard-
less of their HPV status (p16-/p53+/HPV-HR and p16-/
p53+/HPV-). These two groups also were among the
lowest in 2-year median survival. Two other joint groups
had similar, elevated recurrence-free HRs compared to
the referent, despite having the exact opposite joint
marker profile from each other (p16-/p53-/HPV-, HR =
8.6; and p16+/p53+/HPV-HR, HR = 9.8). In yet another
contrast, despite overexpression of p53 in those with
p16+/p53+/HPV-HR tumors, disease-specific survival
was similar to the referent group which is p53-; yet the
p16+/p53+/HPV-HR group had a 10-fold higher risk of
recurrence compared to the referent. The evidence also
indicated that compared to the referent joint group, the
adjusted hazard ratios for recurrence-free survival were
significantly worse or elevated in all other biomarker
groups (HRs = 5.5-19.7). Because of the small sample
size in some groups, these findings need additional
numbers of patients to confirm our conclusions. This
need for larger numbers of samples will be difficult to
achieve because to date, few large studies have examined
multiple biomarkers.
The large number of patients in this study enabled us
to assess joint biomarkers and clinical outcomes while
controlling for other risk factors associated with survival.
We found strong evidence for alcohol and tobacco use
to be associated with cases who were detected with
HPV-HR tumors whether examined as individual or as
joint markers, in contrast to some studies that believe
that HPV and alcohol/tobacco risk factors characterize
two distinct HNC tumor groups [20,21].
Two previous Italian studies [19,22] evaluated a small
group of oropharyngeal carcinomas for p16, p53, and
HPV but did not perform multivariate statistical ana-
lyses to control for confounding or examine survival for
multiple gene interaction effects. A recent study in the
U.S. [23] with limited sample size and several in Europe
[24-26] also examined multiple markers and evaluated
only OP survival. Not all cases were assessed for all
tumor markers as done in this study and survival ana-
lyses in those and other studies were limited to p53/
H P Vo rp 1 6 / H P Vg r o u p s[ 6 , 1 1 , 1 6 ] .F u r t h e r m o r e ,w e
included all major head and neck sites (oropharynx, oral
cavity, and larynx/hypopharynx) since analyses showed
no differences in joint marker outcomes by tumor site.
Only 70% of our cases were diagnosed in stages III/IV
compared to over 91% in the Italian study of patients
and a much smaller portion of our HNC cases received
surgery and radiation (35% versus 64%) [19,22]. These
patient differences may account for variations shown in
joint molecular profiles and prognostic outcomes
between our studies. In contrast to Licitra et al., [19] we
did not find that HPV-HR tumors were a distinct mole-
cular group after evaluating a more complete molecular
profile of the patient malignancies.
Conclusions
Our findings highlight the complexity and importance of
understanding the molecular pathways in tumor pro-
gression and the importance of characterizing the com-
bination of these markers to more precisely identify
clinical outcomes. Subgroup analyses by site need to be
evaluated to be useful for clinicians to interpret. This
will require larger numbers of patients defined by site,
subsite, stage, and histology as well as by biomarker sta-
tus to improve the application of these joint biomarker
groups for clinical use.
Methods
Patients
The study population consisted of 237 histologically
confirmed HNC patients enrolled between 1994 to 2004
at the University of Iowa Hospitals and Clinics for
whom p16 and p53 immunohistostaining (IHC) and
HPV detection had been performed at the time of
analyses. Patients signed a human subjects consent form
and completed a self-administered questionnaire regard-
ing demographic characteristics and high risk HNC can-
cer behaviors (i.e. smoking, alcohol use, sexual
practices), and a medical history including HPV-related
diseases and lesions. Pathology records included prior
cancer history, histology, stage, grade, nodal involve-
ment, treatment, and outcome.
Laboratory Methods
Formalin-fixed, paraffin-embedded tumor blocks were
obtained to corroborate malignancy and tumor grade
based on prepared hematoxylin and eosin-stained (H&E)
slides. The tumor block with the highest percentage of
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p16, p53 IHC. Tumor staging was based on the 1997
American Joint Committee on Cancer (AJCC) criteria
[24] and grade, histology, and tumor site were obtained
from the pathology report. Most cases were squamous
cell carcinoma (SCC) with about 9% carcinomas of
other carcinoma types. Because nonSCC histologies
have not been routinely evaluated in HNC tumors and
because of the established association between adeno-
carcinoma of the cervix and HPV-HR, we evaluated the
molecular markers in these cases as well. Tumor sites
were categorized as oral cavity, oropharynx, and larynx/
hypopharynx (excluding nasopharynx) as recommended
in the AJCC Cancer Staging Manual [27].
Laser capture microdissection (LCM) was performed to
verify that HPV DNA detected in the same cut series was
indeed present in the cancer cells and not in the adjacent
normal epithelium when tissue specimens had less than
10% of tumor tissue or when they were initially found to
contain an HPV nononcogenic, low-risk type as
described previously [3]. If the HPV or b-globin results
from block tissues or LCM were divergent, the LCM
findings were used in the analysis because of its higher
sensitivity and accuracy in targeting tumor cells. The
Qiagen DNA Tissue Kit protocol was used in the DNA
extraction. HPV DNA was detected by PCR with MYO9/
11 primers and dot blot hybridization. Dot blot positive
samples were amplified by with primers of GP5+/GP6+
or GP5+/MY09 and typed by automated sequencing
resulting in all types identified through the BLAST sys-
tem. Detailed procedures have been described elsewhere
[3]. HPV- specimens are defined as those that are nega-
tive for HPV-HR types; HPV low-risk types are included
in the HPV- group because they are nononcogenic and
not associated with an increased risk of HNC [3,16].
P16 and p53 IHC was performed as described pre-
viously [7]. Standard positive and negative p16 and p53
slides were used as controls in their respective assays.
Then tissue sections were counter-stained with hema-
toxylin, dehydrated in graded alcohol, cleared in xylene,
and mounted. All IHC slides were reviewed by one
pathologist (THH) and strong nuclear and cytoplasmic
staining defined a positive reaction. The p16 and p53
staining was scored on a semi-quantitative scale and
then dichotomized to positive and negative for statistical
analyses. The initial scale for both biomarkers was as
follows: 1 = negative for staining, 2 = <10% positive
staining, 3 = 10%-80% positive, 4 = ≥80%<100% positive;
and 5 = 100% positive in every tumor cell. These cate-
gories were collapsed with category 1 defined as nega-
tive, and 2, 3, 4, or 5 defined as positive. There were
only 2 cases in category = 2 of p16+ and 4 cases of p53
+; category 3 included 7 p16+ and 18 p53+ cases. The
numbers in these two categories did not alter the
statistical findings when included in the analyses of this
large study. Only stained tumor cells with a positive
result were defined as positive and nontumor cells such
as multinucleated giant cells and epithelia were not
included.
Statistical Methods
Risk factors examined in the analyses were age, gender,
alcohol, tobacco, tumor site, grade, stage, and treatment.
Logistic regression was used to calculate the adjusted
significance of associations between HPV, p16 and p53
and demographic characteristics and risk factors. Results
for SCC and nonSCC were compared for differences in
biomarker frequencies and in adjusted multivariate
statistical analyses. Except for the few significant differ-
ences between these two groups, results are reported for
the combined histologies in the analyses. Statistical
comparisons in median survival were analyzed using the
median Wilcoxon test. Survival curves were estimated
by the Kaplan-Meier method and differences between
groups were assessed using the log-rank test. Hazard
ratios (HRs) were estimated using the Cox proportional
hazards model. Proportional hazards and other model-
building assumptions were assessed. Overall and
disease-specific survival, and recurrence were measured
in years from the date of diagnosis until death (or recur-
rence) or until the patient was last known to be alive.
Disease-specific survival was based on events related to
deaths from HNC. Patients with an indeterminate cause
of death were excluded from the overall survival analy-
sis. Date of death or date last known to be alive was
obtained from the NCI Iowa SEER Cancer Registry [28],
university hospital tumor registry, and National Death
Index [29]. All independent variables were assessed for
multiplicative interactions in the models and the joint
biomarker groups were assessed for additive interactions
with the synergy index
10. Statistical results were based
on two-tailed tests with statistical significance at p <
0.05. Statistical analyses were performed using SAS 9.1.
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